Tenaya Therapeutics Inc (TNYA)
4.39
+0.14
(+3.29%)
USD |
NASDAQ |
May 17, 13:05
Tenaya Therapeutics Cash from Financing (Quarterly): 46.77M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 46.77M |
December 31, 2023 | 0.371M |
September 30, 2023 | 0.00 |
June 30, 2023 | 4.179M |
March 31, 2023 | -0.501M |
December 31, 2022 | 77.49M |
September 30, 2022 | 0.006M |
June 30, 2022 | 0.26M |
March 31, 2022 | 0.015M |
Date | Value |
---|---|
December 31, 2021 | -0.021M |
September 30, 2021 | 190.27M |
June 30, 2021 | -1.298M |
March 31, 2021 | 20.02M |
December 31, 2020 | 85.92M |
September 30, 2020 | 30.70M |
June 30, 2020 | -0.021M |
March 31, 2020 | 30.67M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.298M
Minimum
Jun 2021
190.27M
Maximum
Sep 2021
28.52M
Average
0.371M
Median
Dec 2023
Cash from Financing (Quarterly) Benchmarks
Bristol-Myers Squibb Co | 14.64B |
Solid Biosciences Inc | 0.505M |
Dyne Therapeutics Inc | 408.39M |
Sana Biotechnology Inc | 186.40M |
Prime Medicine Inc | 157.33M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -28.66M |
Cash from Investing (Quarterly) | -4.489M |
Free Cash Flow | -101.62M |
Free Cash Flow Per Share (Quarterly) | -0.3609 |
Free Cash Flow Yield | -30.59% |